8-K: Quantum-Si Announces Full Commercial Launch and 2024 Financial Guidance

Quantum-Si reports fourth quarter and full year 2023 results, finalizes commercial readiness, and provides 2024 financial guidance.

Summary

• Quantum-Si reported $400,000 in revenue for the fourth quarter of 2023 and $1.1 million for the full year, with a gross margin of 45% for both periods.
• The company's net loss was $22.0 million for the fourth quarter and $96.0 million for the full year 2023.
• Adjusted EBITDA was negative $25.1 million for the fourth quarter and negative $94.3 million for the full year.
• Quantum-Si is finalizing commercial readiness for a full commercial launch of its Platinum instrument by the end of Q1 2024.
• The company launched version 2 of its sequencing kit in early February 2024 and plans to release version 3 by the end of Q3 2024.
• Full year 2024 financial guidance includes revenue between $3.7 and $4.2 million, adjusted total operating expenses less than $103 million, and total cash usage less than $100 million.
• The company's cash and cash equivalents and investments in marketable securities were $257.7 million as of December 31, 2023, which is expected to provide a runway into 2026.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the progress in commercialization and product development, but tempered by the significant losses and the need to achieve revenue growth. The company is making progress but is still in an early stage.

Positives

• The company is finalizing commercial readiness for the full launch of its Platinum instrument.
• The launch of version 2 of the sequencing kit was within the previously provided timeline.
• The company is seeing an acceleration in its R&D pipeline.
• The company has added a third international distribution partner in Japan.
• Operating expenses have decreased as the company focused on efficient capital deployment.
• Net loss has decreased compared to the prior year.

Negatives

• The company reported a net loss of $22.0 million for Q4 2023 and $96.0 million for the full year.
• Adjusted EBITDA was negative $25.1 million for Q4 2023 and negative $94.3 million for the full year.
• The periodic gross margin rate is expected to be variable in the near term.

Risks

• The company's actual results may differ from its expectations, estimates, and projections.
• The company's ability to grow and manage growth profitably and retain its key employees is a risk.
• The company's ability to raise financing in the future is a risk.
• The success, cost and timing of the company's product development and commercialization activities are risks.
• The commercialization and adoption of the company's existing products and the success of any product the company may offer in the future are risks.
• The company's ability to compete with other companies in the proteomic analysis market is a risk.
• The company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing are risks.

Future Outlook

The company expects to commence full commercial launch of its Platinum instrument by the end of Q1 2024 and anticipates a cash runway into 2026 based on current cash reserves. They also provided full year 2024 financial guidance.

Management Comments

• Jeff Hawkins, President and Chief Executive Officer of Quantum-Si, stated that they made great progress in the fourth quarter of 2023 and are seeing the early results of that work.
• Hawkins also mentioned that they are excited about the acceleration they are seeing in their R&D pipeline and believe they are in a strong position to deliver a steady cadence of product enhancements and new capabilities to the market in 2024 and beyond.
• Hawkins announced that they expect to commence their full commercial launch of their Platinum instrument by the end of Q1 2024.

Industry Context

This announcement comes as the proteomics field is gaining momentum, with increasing interest in protein sequencing technologies. Quantum-Si is positioning itself as a key player in this space with its semiconductor chip-based technology.

Comparison to Industry Standards

• Quantum-Si's revenue of $1.1 million for the full year 2023 is relatively low compared to established companies in the life sciences tools sector, such as Illumina or Thermo Fisher Scientific, which report billions in annual revenue.
• The company's gross margin of 45% is within the typical range for companies in the life sciences tools industry, but it is expected to be variable in the near term.
• The company's significant net losses and negative adjusted EBITDA are not uncommon for early-stage companies in the biotech sector that are investing heavily in R&D and commercialization.
• The company's cash runway into 2026 is a positive sign, but it will need to demonstrate significant revenue growth to achieve profitability.
• Competitors in the protein sequencing space include companies like SomaLogic and Nautilus Biotechnology, which are also developing innovative technologies and are at various stages of commercialization.

Stakeholder Impact

• Shareholders will be interested in the company's progress towards commercialization and revenue growth.
• Employees will be impacted by the company's growth and development.
• Customers will benefit from the company's new products and technologies.
• Suppliers will be impacted by the company's commercial activities.
• Creditors will be interested in the company's financial performance and cash runway.

Next Steps

• The company will commence the full commercial launch of its Platinum instrument by the end of Q1 2024.
• The company will continue to develop and release new versions of its sequencing kits, with version 3 expected by the end of Q3 2024.
• The company will focus on scaling up its commercial resources and expanding its international distribution network.

Key Dates

Keywords

protein sequencing, proteomics, commercial launch, financial results, sequencing kit, Platinum instrument, revenue, EBITDA, operating expenses, financial guidance